Precision Business Insights
Portfolio

 

Neuroendocrine Tumors Therapeutics Market

: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2014-2018 and Forecast 2019-2025

Global Neuroendocrine Tumors Therapeutics Market By Drug Class (Somatostatin Analogues,(Octreotide, Lanreotide, Pasireotide), Chemotherapeutics (Fluorouracil (5-FU), Doxorubicin (Adriamycin) or liposomal doxorubicin (Doxil), Streptozocin, Temozolomide (Temodar), Capecitabine (Xeloda), Dacarbazine (DTIC), Oxaliplatin (Eloxatin)), Targeted Therapeutics, (Sunitinib, Everolimus,Others)), By Indication (Lung NET, Others NET, Gastrointestinal NET, Pancreatic NET), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others) and Geography

Global Neuroendocrine Tumors Therapeutics Market

 

Neuroendocrine tumors (NET) are the abnormal growths which begin in neuroendocrine cells. Neuroendocrine which are similar to the nerve cells and hormones producing cells. Neuroendocrine tumors are rare and can occur anywhere in the body. Most neuroendocrine tumors occur in the small intestine, lungs, rectum, appendix, and pancreas. Neuroendocrine tumors can be noncancerous (benign) or cancerous (malignant). NETs will arises from several neuroendocrine cells whose normal functions are to serve at neuroendocrine interface. Neuroendocrine cells will present throughout the body where hormones are produced but not only in the endocrine glands.

 

Neuroendocrine tumors therapeutics market expected to grow owing to increase in initiatives taken by various international organizations like American Association for Cancer Research and World Health Organization to treat neuroendocrine tumors are expected to drive the growth of the market. AACR provided $250,000 fund for the Prevention of neuroendocrine tumors. Rise in health care expenditure, increase in prevalence rate of neuroendocrine tumors in developing regions is anticipated to drive global neuroendocrine tumors market.  Though the market is expected to witness healthy growth, lack of skilled healthcare professional and lower adoption of advanced treatment technologies in the developing economies are key restraints for neuroendocrine tumors market.

 

 Neuroendocrine Tumours Therapeutics Market

Neuroendocrine Tumors Therapeutics Market

 

The global neuroendocrine tumors therapeutics market is segmented on the basis of the Drug Class, indication, distribution channel, and geographical regions.

 

Based on Drug Class, this Market is segmented as

  • Somatostatin Analogues
    • Octreotide
    • Lanreotide
    • Pasireotide
  • Chemotherapeutics
    • Fluorouracil (5-FU)
    • Doxorubicin (Adriamycin) or liposomal doxorubicin (Doxil)
    • Streptozocin
    • Temozolomide (Temodar)
    • Capecitabine (Xeloda)
    • Dacarbazine (DTIC)
    • Oxaliplatin (Eloxatin)
  • Targeted Therapeutics
    • Sunitinib
    • Everolimus
  • Others

Based on indication, this market is segmented as

  • Lung NET
  • Others NET
  • Gastrointestinal NET
  • Pancreatic NET

Based on distribution channel, this market is segmented as:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

 

The neuroendocrine tumors treatment market is expected to gain steady traction in the foreseeable future as there are many novel drugs are in pipeline. Increase in NET incidence and prevalence globally. As per the estimation of Canadian Cancer Society (CCS), about 315 individuals were diagnosed with endocrine cancers in 2012 in Canada and rate is raising with early stage diagnosis and migration. Moreover, rise in survival rate of neuroendocrine tumors by treating with various medications are expected to have a positive impact on neuroendocrine tumors market. According to the study published in the JAMA Oncology Journal (2017), the survival rate for all neuroendocrine tumour treatment have improved, especially for distant-stage gastrointestinal neuroendocrine tumour treatment and pancreatic neuroendocrine tumour treatment.

 

Based on the geographical regions, global neuroendocrine tumors therapeutics market is segmented into five key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.  According to Cancer.Net, approximately 8,000 people are identified with neuroendocrine cancer every year in the U.S. Several key players functioning in neuroendocrine tumors therapeutics are based in the U.S. Hence, in North America became main market for product launch and research and development activities. Furthermore, entrenched infrastructure and favorable reimbursement scenario are the major factors accountable for the strengthening of North America’s neuroendocrine tumors therapeutics market. Europe is the second largest market for neuroendocrine tumors therapeutics, followed by Asia-Pacific. Increase in prevalence of neuroendocrine cancer in Asia-Pacific along with the refining economic scenario is expected to play an important role in driving the market growth in the region.

 

Some of the players operating in the global neuroendocrine tumors therapeutics  include Pfizer Inc., (U.S), Eli Lilly & Company (U.S.), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd.(Switzerland), Ipsen (France), Amgen, Inc. (U.S.), Teva Pharmaceuticals, Ltd. (Israel), and Bristol-Myers Squibb (U.S.).

 

  • In  2016, Novartis received the U.S. FDA approval for its Afinitor®(everolimus) tablets for the treatment of adult patients with progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal or lung origin.
  • In 2014, Ipsen Biopharmaceuticals, Inc., received U.S.FDA approval for Somatuline®Depot® (lanreotide) Injection 120 mg to treat gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients

 

Report Outline:

  • The report provides granular level information about the market size, regional market share and forecast from 2017-2023
  • The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
  • The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
  • The report tracks recent innovations, key developments and startup’s details that are working in the industry
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

1. Executive summary

2. Global Neuroendocrine Tumors Therapeutics Market Introduction

                    2.1. Global Neuroendocrine Tumors Therapeutics Market – Taxonomy

                    2.2. Global Neuroendocrine Tumors Therapeutics Market –Definitions

                                     2.2.1. Drug Class

                                     2.2.2. Indication

                                     2.2.3. Distribution Channel

3.Global Neuroendocrine Tumors Therapeutics Market Dynamics

                    3.1. Drivers

                    3.2. Restraints

                    3.3. Opportunities/Unmet Needs of the Market

                    3.4. Trends

                    3.5. Global Neuroendocrine Tumors Therapeutics Market Dynamics – Factors Impact Analysis

                    3.6. Global Neuroendocrine Tumors Therapeutics Market – Regulations

                                     3.6.1. U.S

                                     3.6.2. Europe

                                     3.6.3. Japan

                                     3.6.4. China

                    3.7. Global Neuroendocrine Tumors Therapeutics Market – Product Innovations

4. Global Neuroendocrine Tumors Therapeutics Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024

                    4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                    4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

                    4.3. Market Opportunity Analysis

5. Global Neuroendocrine Tumors Therapeutics Market, By Drug Class, 2013 – 2017 and Forecast, 2018 – 2024

                    5.1. Somatostatin Analogues

                                     5.1.1. Octreotide

                                                   5.1.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                                                   5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                                                   5.1.1.3. Market Opportunity Analysis

                                     5.1.2. Lanreotide

                                                   5.1.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                                                   5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                                                   5.1.2.3. Market Opportunity Analysis

                                     5.1.3. Pasireotide

                                                   5.1.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                                                   5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                                                   5.1.3.3. Market Opportunity Analysis

                    5.2. Chemotherapeutics

                                     5.2.1. Fluorouracil (5-FU)

                                                   5.2.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                                                   5.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                                                   5.2.1.3. Market Opportunity Analysis

                                     5.2.2. Doxorubicin (Adriamycin) or liposomal doxorubicin (Doxil)

                                                   5.2.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                                                   5.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                                                   5.2.2.3. Market Opportunity Analysis

                                     5.2.3. Streptozocin

                                                   5.2.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                                                   5.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                                                   5.2.3.3. Market Opportunity Analysis

                                     5.2.4. Capecitabine (Xeloda)

                                                   5.2.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                                                   5.2.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                                                   5.2.4.3. Market Opportunity Analysis

                                     5.2.5. Dacarbazine (DTIC)

                                                   5.2.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                                                   5.2.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                                                   5.2.5.3. Market Opportunity Analysis

                                     5.2.6. Temozolomide (Temodar)

                                                   5.2.6.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                                                   5.2.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                                                   5.2.6.3. Market Opportunity Analysis

                                     5.2.7. Oxaliplatin (Eloxatin)

                                                   5.2.7.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                                                   5.2.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                                                   5.2.7.3. Market Opportunity Analysis

                    5.3. Targeted Therapeutics

                                     5.3.1. Sunitinib

                                                   5.3.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                                                   5.3.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                                                   5.3.1.3. Market Opportunity Analysis

                                     5.3.2. Everolimus

                                                   5.3.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                                                   5.3.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                                                   5.3.2.3. Market Opportunity Analysis

                    5.4. Others

                                     5.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                                     5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                                     5.4.3. Market Opportunity Analysis

6. Global Neuroendocrine Tumors Therapeutics Market Forecast, By Indication, 2013 – 2017 and Forecast, 2018 – 2024

                    6.1. Lung NET

                                     6.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                                     6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                                     6.1.3. Market Opportunity Analysis

                                     6.2. Gastrointestinal NET

                                     6.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                                     6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                                     6.2.3. Market Opportunity Analysis

                    6.3. Pancreatic NET

                                     6.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                                     6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                                     6.3.3. Market Opportunity Analysis

                    6.4. Others

                                     6.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                                     6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                                     6.4.3. Market Opportunity Analysis

7. Global Neuroendocrine Tumors Therapeutics Market Forecast, By Distribution Channel , 2013 – 2017 and Forecast, 2018 – 2024

                    7.1. Retail Pharmacies

                                     7.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                                     7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                                     7.1.3. Market Opportunity Analysis

                    7.2. Hospital Pharmacies

                                     7.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                                     7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                                     7.2.3. Market Opportunity Analysis

                    7.3. Others

                                     7.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                                     7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                                     7.3.3. Market Opportunity Analysis

8. Global Neuroendocrine Tumors Therapeutics Market Forecast, By Region, 2013 – 2017 and Forecast, 2018 – 2024

                    8.1. North America

                                     8.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                                     8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                                     8.1.3. Market Opportunity Analysis

                    8.2. Europe

                                     8.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                                     8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                                     8.2.3. Market Opportunity Analysis

                    8.3. Asia-Pacific

                                     8.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                                     8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                                     8.3.3. Market Opportunity Analysis

                    8.4. Latin America

                                     8.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                                     8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                                     8.4.3. Market Opportunity Analysis

                    8.5. Middle East and Africa

                                     8.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                                     8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                                     8.5.3. Market Opportunity Analysis

                    8.6. Global Neuroendocrine Tumors Therapeutics Market – Opportunity Analysis Index, By Drug Class, Indication, Distribution Channel and Region, 2018 – 2024

9. North America Neuroendocrine Tumors Therapeutics Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024

                                     9.1.1. Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

                                                   9.1.1.1. Somatostatin Analogues

                                                            9.1.1.1.1. Octreotide

                                                            9.1.1.1.2. Lanreotide

                                                            9.1.1.1.3. Pasireotide

                                                   9.1.1.2. Chemotherapeutics

                                                            9.1.1.2.1. Fluorouracil (5-FU)

                                                            9.1.1.2.2. Doxorubicin (Adriamycin) or liposomal doxorubicin (Doxil)

                                                            9.1.1.2.3. Streptozocin

                                                            9.1.1.2.4. Temozolomide (Temodar)

                                                            9.1.1.2.5. Capecitabine (Xeloda)

                                                            9.1.1.2.6. Dacarbazine (DTIC)

                                                            9.1.1.2.7. Oxaliplatin (Eloxatin)

                                                   9.1.1.3. Targeted Therapeutics

                                                            9.1.1.3.1. Sunitinib

                                                            9.1.1.3.2. Everolimus

                                                   9.1.1.4. Others

                                     9.1.2. Indication Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

                                                   9.1.2.1. Lung NET

                                                   9.1.2.2. Others NET

                                                   9.1.2.3. Gastrointestinal NET

                                                   9.1.2.4. Pancreatic NET

                                     9.1.3. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

                                                   9.1.3.1. Retail Pharmacies

                                                   9.1.3.2. Hospital Pharmacies

                                                   9.1.3.3. Others

                                     9.1.4. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

                                                   9.1.4.1. US

                                                   9.1.4.2. Canada

                                     9.1.5. North America Neuroendocrine Tumors Therapeutics Market – Opportunity Analysis Index, By Drug Analysis, Indication, Distribution Channel, and Country, 2018 – 2024

                                     9.1.6. North America Neuroendocrine Tumors Therapeutics Market Dynamics – Trends

10. Europe Neuroendocrine Tumors Therapeutics Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024

                                     10.1.1. Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

                                                   10.1.1.1. Somatostatin Analogues

                                                                10.1.1.1.1. Octreotide

                                                                10.1.1.1.2. Lanreotide

                                                                10.1.1.1.3. Pasireotide

                                                   10.1.1.2. Chemotherapeutics

                                                                10.1.1.2.1. Fluorouracil (5-FU)

                                                                10.1.1.2.2. Doxorubicin (Adriamycin) or liposomal doxorubicin (Doxil)

                                                                10.1.1.2.3. Streptozocin

                                                                10.1.1.2.4. Temozolomide (Temodar)

                                                                10.1.1.2.5. Capecitabine (Xeloda)

                                                                10.1.1.2.6. Dacarbazine (DTIC)

                                                                10.1.1.2.7. Oxaliplatin (Eloxatin)

                                                   10.1.1.3. Targeted Therapeutics

                                                                10.1.1.3.1. Sunitinib

                                                                10.1.1.3.2. Everolimus

                                                   10.1.1.4. Others

                                     10.1.2. Indication Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

                                                   10.1.2.1. Lung NET

                                                   10.1.2.2. Others NET

                                                   10.1.2.3. Gastrointestinal NET

                                                   10.1.2.4. Pancreatic NET

                                     10.1.3. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

                                                   10.1.3.1. Retail Pharmacies

                                                   10.1.3.2. Hospital Pharmacies

                                                   10.1.3.3. Others

                                     10.1.4. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

                                                              10.1.4.1. Germany

                                                              10.1.4.2. UK

                                                              10.1.4.3. France

                                                              10.1.4.4. Spain

                                                              10.1.4.5. Italy

                                                   10.1.4.6. Russia

                                                   10.1.4.7. Poland

                                                              10.1.4.8. Rest of Europe

                                     10.1.5. Europe Neuroendocrine Tumors Therapeutics Market – Opportunity Analysis Index, By  Drug Analysis, Indication, Distribution Channel and Country, 2018 – 2024

                                     10.1.6. Europe Neuroendocrine Tumors Therapeutics Market Dynamics – Trends

11. Asia-Pacific Neuroendocrine Tumors Therapeutics Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024

                                     11.1.1. Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

                                                  11.1.1.1. Somatostatin Analogues

                                                              11.1.1.1.1. Octreotide

                                                              11.1.1.1.2. Lanreotide

                                                              11.1.1.1.3. Pasireotide

                                                   11.1.1.2. Chemotherapeutics

                                                              11.1.1.2.1. Fluorouracil (5-FU)

                                                              11.1.1.2.2. Doxorubicin (Adriamycin) or liposomal doxorubicin (Doxil)

                                                              11.1.1.2.3. Streptozocin

                                                              11.1.1.2.4. Temozolomide (Temodar)

                                                              11.1.1.2.5. Capecitabine (Xeloda)

                                                              11.1.1.2.6. Dacarbazine (DTIC)

                                                              11.1.1.2.7. Oxaliplatin (Eloxatin)

                                                   11.1.1.3. Targeted Therapeutics

                                                              11.1.1.3.1. Sunitinib

                                                              11.1.1.3.2. Everolimus

                                                   11.1.1.4. Others

                                     11.1.2. Indication Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

                                                   11.1.2.1. Lung NET

                                                   11.1.2.2. Others NET

                                                   11.1.2.3. Gastrointestinal NET

                                                   11.1.2.4. Pancreatic NET

                                     11.1.3. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

                                                   11.1.3.1. Retail Pharmacies

                                                   11.1.3.2. Hospital Pharmacies

                                                   11.1.3.3. Others

                                     11.1.4. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn),

Y-o-Y Growth (%), and Market Share (%)

                                                   11.1.4.1. Japan

                                                   11.1.4.2. China

                                                   11.1.4.3. India

                                                   11.1.4.4. ASEAN

                                                   11.1.4.5. Australia & New Zealand

                                                   11.1.4.6. Rest of Asia-Pacific

                                     11.1.5. Asia-Pacific Neuroendocrine Tumors Therapeutics Market – Opportunity Analysis Index, By  Drug Analysis, Indication, Distribution Channel and Country, 2018 – 2024

                                     11.1.6. Europe Neuroendocrine Tumors Therapeutics Market Dynamics – Trends

12. Latin America Neuroendocrine Tumors Therapeutics Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024

                                     12.1.1. Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

                                                   12.1.1.1. Somatostatin Analogues

                                                              12.1.1.1.1. Octreotide

                                                              12.1.1.1.2. Lanreotide

                                                              12.1.1.1.3. Pasireotide

                                                   12.1.1.2. Chemotherapeutics

                                                              12.1.1.2.1. Fluorouracil (5-FU)

                                                              12.1.1.2.2. Doxorubicin (Adriamycin) or liposomal doxorubicin (Doxil)

                                                              12.1.1.2.3. Streptozocin

                                                              12.1.1.2.4. Temozolomide (Temodar)

                                                              12.1.1.2.5. Capecitabine (Xeloda)

                                                              12.1.1.2.6. Dacarbazine (DTIC)

                                                              12.1.1.2.7. Oxaliplatin (Eloxatin)

                                                   12.1.1.3. Targeted Therapeutics

                                                               12.1.1.3.1. Sunitinib

                                                               12.1.1.3.2. Everolimus

                                                   12.1.1.4. Others

                                     12.1.2. Indication Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

                                                   12.1.2.1. Lung NET

                                                   12.1.2.2. Others NET

                                                   12.1.2.3. Gastrointestinal NET

                                                   12.1.2.4. Pancreatic NET

                                     12.1.3. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

                                                   12.1.3.1. Retail Pharmacies

                                                   12.1.3.2. Hospital Pharmacies

                                                   12.1.3.3. Others

                                     12.1.4. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

                                                   12.1.4.1. Brazil

                                                   12.1.4.2. Mexico

                                                   12.1.4.3. Argentina

                                                   12.1.4.4. Venezuela

                                                   12.1.4.5. Rest of Latin America

                                     12.1.5. Latin America Neuroendocrine Tumors Therapeutics Market – Opportunity Analysis Index, By  Drug Analysis, Indication, Distribution Channel and Country, 2018 – 2024

                                     12.1.6. Latin America Neuroendocrine Tumors Therapeutics Market Dynamics – Trends

13. Middle East and Africa Neuroendocrine Tumors Therapeutics Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024

                                     13.1.1. Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

                                                   13.1.1.1. Somatostatin Analogues

                                                              13.1.1.1.1. Octreotide

                                                              13.1.1.1.2. Lanreotide

                                                              13.1.1.1.3. Pasireotide

                                                   13.1.1.2. Chemotherapeutics

                                                              13.1.1.2.1. Fluorouracil (5-FU)

                                                              13.1.1.2.2. Doxorubicin (Adriamycin) or liposomal doxorubicin (Doxil)

                                                              13.1.1.2.3. Streptozocin

                                                              13.1.1.2.4. Temozolomide (Temodar)

                                                              13.1.1.2.5. Capecitabine (Xeloda)

                                                              13.1.1.2.6. Dacarbazine (DTIC)

                                                              13.1.1.2.7. Oxaliplatin (Eloxatin)

                                                   13.1.1.3. Targeted Therapeutics

                                                              13.1.1.3.1. Sunitinib

                                                              13.1.1.3.2. Everolimus

                                                   13.1.1.4. Others

                                     13.1.2. Indication Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

                                                   13.1.2.1. Lung NET

                                                   13.1.2.2. Others NET

                                                   13.1.2.3. Gastrointestinal NET

                                                   13.1.2.4. Pancreatic NET

                                     13.1.3. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

                                                   13.1.3.1. Retail Pharmacies

                                                   13.1.3.2. Hospital Pharmacies

                                                   13.1.3.3. Others

                                     13.1.4. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

                                                   13.1.4.1. Gulf Cooperation Council (GCC) Countries

                                                   13.1.4.2. Israel

                                                   13.1.4.3. South Africa

                                                   13.1.4.4. Rest of MEA

                                     13.1.5. MEA Neuroendocrine Tumors Therapeutics Market – Opportunity Analysis Index by Drug Analysis, Indication, Distribution Channel and Country, 2018 – 2024

                                     13.1.6. MEA Neuroendocrine Tumors Therapeutics Market Dynamics – Trends

14. Competition Landscape

                    14.1. Strategic Dashboard of Top Market Players

                    14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)

                                     14.2.1. Pfizer Inc., (U.S)

                                     14.2.2. Eli Lilly & Company (U.S.)

                                     14.2.3. Novartis AG (Switzerland)

                                     14.2.4. F. Hoffmann-La Roche Ltd. (Switzerland)

                                     14.2.5. Ipsen (France)

                                     14.2.6. Amgen, Inc. (U.S.)

                                     14.2.7. Teva Pharmaceuticals, Ltd. (Israel)

                                     14.2.8. Bristol-Myers Squibb (U.S.)

15. Research Methodology

16. Key Assumptions and Acronyms

$ 3,000.00$ 8,900.00
Clear selection

Select License Type

Databank $ 3,000.00
spinner
Single User $ 4,400.00
spinner
Multiple User $ 6,600.00
spinner
Corporate User $ 8,900.00
spinner
buy now spinner
FacebookTwitterLinkedinEmail

Our Clients

Testimonials